Platform providers like MediRecords are increasingly introducing AI agents to support the generation of patient summaries, ...

Public-private partnership aims to improve osteoarthritis research, diagnosis and treatment----PROBE will leverage data from over 70 million ...

Under the terms of the agreement, Caris is eligible to receive upfront and near-term payments of $25 million and is also ...

Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced that Providence Swedish Cancer Institute and the ...

Researchers have reported initial findings from a public-private partnership between the ECOG-ACRIN Cancer Research Group and Caris Life Sciences to improve recurrence risk assessment in early-stage ...

All in all, PHAT has 6 recent analyst reviews that break down into 5 Buys and 1 Hold, giving the stock a Strong Buy consensus rating. The shares are priced at $17.66 and have an average price target ...

Biopharma may see a happier year ahead in 2026 than in recent years, according to analysts at William Blair. For one thing, the industry’s top stocks have recovered from lows that stretched into last ...

Starton Holdings plans $40M IPO for cancer drug delivery innovations, but weak IP and limited backing make this a potentially ...

REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median ...

This milestone marks Enveda's third asset to enter clinical development, following ENV-294 (atopic dermatitis and asthma) and ENV-308 (obesity), underscoring the productivity of the company's platform ...

Expanding bispecific antibody access for multiple myeloma involves collaboration between academic centers and community ...

The CUTX-101 NDA was initially granted Priority Review by the FDA and is supported by positive topline clinical efficacy ...